852 related articles for article (PubMed ID: 17590391)
1. Characterization of mutations in the VP(1) region of Sabin strain type 1 polioviruses isolated from vaccine-associated paralytic poliomyelitis cases in Iran.
Rahimi P; Tabatabaie H; Gouya MM; Zahraie M; Mahmudi M; Ziaie A; Rad KS; Shahmahmudi Sh; Musavi T; Azad TM; Nategh R
J Clin Virol; 2007 Aug; 39(4):304-7. PubMed ID: 17590391
[TBL] [Abstract][Full Text] [Related]
2. Vaccine-associated paralytic poliomyelitis and other diseases with acute flaccid paralysis syndrome in Belarus.
Samoilovich EO; Feldman EV; Yermalovich MA; Protas II; Titov LP
Cent Eur J Public Health; 2003 Dec; 11(4):213-8. PubMed ID: 14768785
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary.
Kapusinszky B; Molnár Z; Szomor KN; Berencsi G
FEMS Immunol Med Microbiol; 2010 Mar; 58(2):211-7. PubMed ID: 19863665
[TBL] [Abstract][Full Text] [Related]
4. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2004-June 2005.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(38):958-61. PubMed ID: 16195695
[TBL] [Abstract][Full Text] [Related]
5. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
Chowdhary R; Dhole TN
J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
[TBL] [Abstract][Full Text] [Related]
6. Laboratory surveillance for wild and vaccine-derived polioviruses--worldwide, January 2007-June 2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Sep; 57(35):967-70. PubMed ID: 18772852
[TBL] [Abstract][Full Text] [Related]
7. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.
Băicuş A; Persu A; Combiescu M; Aubert-Combiescu A
Roum Arch Microbiol Immunol; 2007; 66(1-2):44-50. PubMed ID: 18928063
[TBL] [Abstract][Full Text] [Related]
8. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
[TBL] [Abstract][Full Text] [Related]
9. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees.
Friedrich F
Acta Virol; 1996 Jun; 40(3):157-70. PubMed ID: 8891097
[TBL] [Abstract][Full Text] [Related]
10. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2002-June 2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2003 Sep; 52(38):913-6. PubMed ID: 14508441
[TBL] [Abstract][Full Text] [Related]
11. Three cases of paralytic poliomyelitis associated with type 3 vaccine poliovirus strains in Bulgaria.
Korsun N; Kojouharova M; Vladimirova N; Fiore L; Litvinenko I; Buttinelli G; Fiore S; Voynova-Georgieva V; Mladenova Z; Georgieva D
J Med Virol; 2009 Sep; 81(9):1661-7. PubMed ID: 19626606
[TBL] [Abstract][Full Text] [Related]
12. A developing country perspective on vaccine-associated paralytic poliomyelitis.
John TJ
Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
[TBL] [Abstract][Full Text] [Related]
13. Report of the Australian National Polio Reference Laboratory. 1 January 1999 to 30 June 1999. Towards WHO certification as wild poliovirus-free: laboratory surveillance in Australia.
Kennett M; Stambos V; Turnbull A; Ibrahim A; Kelly H
Commun Dis Intell; 1999 Nov; 23(12):324-7. PubMed ID: 10615795
[TBL] [Abstract][Full Text] [Related]
14. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis.
Foiadelli T; Savasta S; Battistone A; Kota M; Passera C; Fiore S; Bino S; Amato C; Lozza A; Marseglia GL; Fiore L
BMC Infect Dis; 2016 Jun; 16():277. PubMed ID: 27287521
[TBL] [Abstract][Full Text] [Related]
15. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
[TBL] [Abstract][Full Text] [Related]
16. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania.
Combiescu M; Guillot S; Persu A; Baicus A; Pitigoi D; Balanant J; Oprisan G; Crainic R; Delpeyroux F; Aubert-Combiescu A
Arch Virol; 2007; 152(4):727-38. PubMed ID: 17195957
[TBL] [Abstract][Full Text] [Related]
17. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia.
Shahmahmoodi S; Parvaneh N; Burns C; Asghar H; Mamishi S; Tabatabaie H; Chen Q; Teimourian S; Gooya MM; Esteghamati AR; Mousavi T; Yousefi M; Farrokhi K; Mashlool M; Kew O; Nategh R
Virus Res; 2008 Oct; 137(1):168-72. PubMed ID: 18674576
[TBL] [Abstract][Full Text] [Related]
18. Oral poliovirus vaccine type 3 from a patient with transverse myelitis is neurovirulent in a transgenic mouse model.
Thorley B; Kelly H; Nishimura Y; Yoon YK; Brussen KA; Roberts J; Shimizu H
J Clin Virol; 2009 Apr; 44(4):268-71. PubMed ID: 19269246
[TBL] [Abstract][Full Text] [Related]
19. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.
Friedrich F
Acta Virol; 2000 Apr; 44(2):109-17. PubMed ID: 10989702
[TBL] [Abstract][Full Text] [Related]
20. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003.
Deshpande JM; Nadkarni SS; Siddiqui ZA
Indian J Med Res; 2003 Dec; 118():217-23. PubMed ID: 14870793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
